Fentiazac

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Fentiazac
Accession Number
DB13217
Type
Small Molecule
Groups
Experimental
Description
Not Available
Structure
Thumb
Synonyms
  • 4-(4-Chlorophenyl)-2-phenyl-5-thiazoleacetic acid
  • 4-(p-Chlorophenyl)-2-phenyl-5-thiazoleacetic acid
  • Fentiazaco
  • Fentiazacum
External IDs
BR 700 / WY-21,894 / WY-21894
International/Other Brands
Donorest / Flogene / Norvedan
Categories
UNII
0YHF6E6NLS
CAS number
18046-21-4
Weight
Average: 329.8
Monoisotopic: 329.0277275
Chemical Formula
C17H12ClNO2S
InChI Key
JIEKMACRVQTPRC-UHFFFAOYSA-N
InChI
InChI=1S/C17H12ClNO2S/c18-13-8-6-11(7-9-13)16-14(10-15(20)21)22-17(19-16)12-4-2-1-3-5-12/h1-9H,10H2,(H,20,21)
IUPAC Name
2-[4-(4-chlorophenyl)-2-phenyl-1,3-thiazol-5-yl]acetic acid
SMILES
OC(=O)CC1=C(N=C(S1)C1=CC=CC=C1)C1=CC=C(Cl)C=C1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Fentiazac.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Fentiazac is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Fentiazac is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Fentiazac is combined with 5-androstenedione.Experimental, Illicit
AbciximabFentiazac may increase the anticoagulant activities of Abciximab.Approved
AcebutololFentiazac may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Fentiazac is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolFentiazac may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcetaminophenThe risk or severity of adverse effects can be increased when Fentiazac is combined with Acetaminophen.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Fentiazac is combined with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Fentiazac.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Fentiazac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Fentiazac is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Fentiazac is combined with Aldosterone.Experimental, Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Fentiazac is combined with Alendronic acid.Approved
AliskirenFentiazac may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Fentiazac is combined with Alminoprofen.Experimental
AlprenololFentiazac may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Fentiazac.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Fentiazac is combined with Amcinonide.Approved
AmikacinFentiazac may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Investigational, Vet Approved
AmilorideFentiazac may decrease the antihypertensive activities of Amiloride.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Fentiazac is combined with Aminosalicylic Acid.Approved
AmiodaroneFentiazac may decrease the antihypertensive activities of Amiodarone.Approved, Investigational
AncrodFentiazac may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Fentiazac.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Fentiazac is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Fentiazac is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Fentiazac is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Fentiazac.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Fentiazac is combined with Antipyrine.Approved, Investigational
Antithrombin III humanFentiazac may increase the anticoagulant activities of Antithrombin III human.Approved
AntrafenineThe risk or severity of adverse effects can be increased when Fentiazac is combined with Antrafenine.Approved
ApixabanFentiazac may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Fentiazac.Investigational
ApramycinFentiazac may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Fentiazac.Approved, Investigational
ArbekacinFentiazac may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinFentiazac may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanFentiazac may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololFentiazac may decrease the antihypertensive activities of Arotinolol.Investigational
AsenapineFentiazac may decrease the antihypertensive activities of Asenapine.Approved
AtamestaneThe risk or severity of adverse effects can be increased when Fentiazac is combined with Atamestane.Investigational
AtenololFentiazac may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Fentiazac.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Fentiazac.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Fentiazac is combined with Azficel-T.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Fentiazac.Approved, Investigational
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Fentiazac.Investigational
BalsalazideThe risk or severity of adverse effects can be increased when Fentiazac is combined with Balsalazide.Approved, Investigational
BecaplerminFentiazac may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Fentiazac is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololFentiazac may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinFentiazac may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Fentiazac is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Fentiazac.Approved
BenorilateThe risk or severity of adverse effects can be increased when Fentiazac is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Fentiazac.Withdrawn
BenzthiazideThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Fentiazac.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Fentiazac is combined with Benzydamine.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Fentiazac.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Fentiazac is combined with Betamethasone.Approved, Vet Approved
BetaxololFentiazac may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Fentiazac.Approved, Investigational
BevantololFentiazac may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Fentiazac is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Fentiazac.Approved, Investigational
BisoprololFentiazac may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinFentiazac may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololFentiazac may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Bromfenac.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Fentiazac.Investigational
BucindololFentiazac may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Fentiazac is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Bufexamac.Approved, Experimental
BufuralolFentiazac may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Fentiazac is combined with Bumadizone.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Fentiazac.Approved
BupranololFentiazac may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Fentiazac.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Fentiazac.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Fentiazac is combined with Candoxatril.Experimental
CapsaicinThe risk or severity of adverse effects can be increased when Fentiazac is combined with Capsaicin.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Fentiazac is combined with Captopril.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Fentiazac is combined with Carbaspirin calcium.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Fentiazac.Approved
CarprofenThe risk or severity of adverse effects can be increased when Fentiazac is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololFentiazac may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolFentiazac may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Fentiazac.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Fentiazac is combined with Celecoxib.Approved, Investigational
CeliprololFentiazac may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinFentiazac may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Fentiazac.Approved, Investigational, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Fentiazac.Approved, Vet Approved
ChlorphenesinThe risk or severity of adverse effects can be increased when Fentiazac is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Fentiazac.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Fentiazac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Fentiazac is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Fentiazac is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Fentiazac is combined with Cilazapril.Approved
CimicoxibThe risk or severity of adverse effects can be increased when Fentiazac is combined with Cimicoxib.Investigational
CinoxacinFentiazac may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinFentiazac may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
CisplatinThe risk or severity of adverse effects can be increased when Fentiazac is combined with Cisplatin.Approved
Citric AcidFentiazac may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Fentiazac is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Fentiazac is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Fentiazac is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Fentiazac is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Fentiazac is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Fentiazac.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Fentiazac.Vet Approved
CloranololFentiazac may decrease the antihypertensive activities of Cloranolol.Experimental
ColesevelamColesevelam can cause a decrease in the absorption of Fentiazac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Fentiazac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Fentiazac is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Fentiazac is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Fentiazac is combined with Cortisone acetate.Approved, Investigational
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Fentiazac.Approved, Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Fentiazac.Experimental
CyclosporineFentiazac may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateFentiazac may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinFentiazac may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidFentiazac may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanFentiazac may increase the anticoagulant activities of Darexaban.Investigational
DeferasiroxThe risk or severity of adverse effects can be increased when Fentiazac is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Fentiazac is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Fentiazac is combined with Delapril.Experimental
DesipramineFentiazac may decrease the antihypertensive activities of Desipramine.Approved, Investigational
DesirudinFentiazac may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Fentiazac is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Fentiazac is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Fentiazac is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Fentiazac is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Fentiazac is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Fentiazac is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Fentiazac is combined with Dexamethasone isonicotinate.Vet Approved
DexibuprofenThe risk or severity of adverse effects can be increased when Fentiazac is combined with Dexibuprofen.Approved, Investigational
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Fentiazac.Approved, Investigational
DextranFentiazac may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DibekacinFentiazac may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
Dibotermin alfaThe risk or severity of adverse effects can be increased when Fentiazac is combined with Dibotermin alfa.Approved, Investigational
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Fentiazac.Approved, Vet Approved
DicoumarolFentiazac may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Fentiazac is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Fentiazac is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Fentiazac is combined with Diflunisal.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Fentiazac is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Fentiazac is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Fentiazac.Approved
DihydrostreptomycinFentiazac may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Fentiazac.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Fentiazac.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Fentiazac.Approved
DrospirenoneFentiazac may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Fentiazac is combined with Droxicam.Withdrawn
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Fentiazac.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Fentiazac.Investigational
Edetic AcidFentiazac may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanFentiazac may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Fentiazac is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Fentiazac is combined with Enalaprilat.Approved
EnoxacinFentiazac may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinFentiazac may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Fentiazac.Experimental
EpanololFentiazac may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Fentiazac.Approved
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Fentiazac.Experimental
EplerenoneFentiazac may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Fentiazac.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Fentiazac.Approved
EquileninThe risk or severity of adverse effects can be increased when Fentiazac is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Fentiazac is combined with Equilin.Approved
EsatenololFentiazac may decrease the antihypertensive activities of Esatenolol.Experimental
EsmololFentiazac may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Fentiazac is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Fentiazac is combined with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Fentiazac.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Fentiazac is combined with Etanercept.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Fentiazac is combined with Ethenzamide.Experimental
Ethyl biscoumacetateFentiazac may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Fentiazac is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Fentiazac.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Fentiazac is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Fentiazac.Investigational, Nutraceutical
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Fentiazac.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Fentiazac.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Fentiazac.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fentiazac is combined with Fenoprofen.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Fentiazac.Vet Approved
FeprazoneThe risk or severity of adverse effects can be increased when Fentiazac is combined with Feprazone.Experimental
Ferulic acidFentiazac may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Fentiazac.Approved, Investigational
Fish oilThe risk or severity of adverse effects can be increased when Fentiazac is combined with Fish oil.Approved, Nutraceutical
FleroxacinFentiazac may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Fentiazac.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Fentiazac is combined with Fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Fentiazac is combined with Fludrocortisone.Approved, Investigational
FluindioneFentiazac may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequineFentiazac may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Fentiazac is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Fentiazac is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Fentiazac.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Fentiazac is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fentiazac is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fentiazac is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fentiazac is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fentiazac is combined with Fluorometholone.Approved, Investigational
FluprednideneThe risk or severity of adverse effects can be increased when Fentiazac is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fentiazac is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Fentiazac.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Fentiazac is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Fentiazac is combined with Flurbiprofen.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Fentiazac is combined with Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fentiazac is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fentiazac is combined with Fluticasone propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Fentiazac.Approved, Nutraceutical, Vet Approved
FondaparinuxFentiazac may increase the anticoagulant activities of Fondaparinux.Approved, Investigational
Fondaparinux sodiumFentiazac may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Fentiazac.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Fentiazac is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fentiazac is combined with Fosinopril.Approved
FramycetinFentiazac may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Fentiazac.Approved, Vet Approved
GabexateFentiazac may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinFentiazac may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinFentiazac may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Fentiazac.Approved, Withdrawn
GemifloxacinFentiazac may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinFentiazac may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinFentiazac may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AFentiazac may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GinsengThe risk or severity of adverse effects can be increased when Fentiazac is combined with Ginseng.Approved, Investigational, Nutraceutical
GrepafloxacinFentiazac may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Fentiazac is combined with Guacetisal.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Fentiazac is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Fentiazac is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Fentiazac is combined with HE3286.Investigational
HeparinFentiazac may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Fentiazac.Investigational
HydralazineFentiazac may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Fentiazac.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Fentiazac is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Fentiazac.Approved, Investigational
Hygromycin BFentiazac may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Fentiazac is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Fentiazac is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Fentiazac.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Fentiazac.Approved, Investigational
IcosapentThe risk or severity of adverse effects can be increased when Fentiazac is combined with Icosapent.Approved, Nutraceutical
IdraparinuxFentiazac may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Fentiazac.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Fentiazac is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Fentiazac is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Fentiazac.Approved
IndenololFentiazac may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Fentiazac.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Fentiazac is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Fentiazac.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Fentiazac.Approved, Investigational
IsepamicinFentiazac may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Fentiazac.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Fentiazac is combined with Istaroxime.Investigational
KanamycinFentiazac may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Fentiazac.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Fentiazac is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Fentiazac.Approved
LabetalolFentiazac may decrease the antihypertensive activities of Labetalol.Approved
LandiololFentiazac may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Fentiazac.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Fentiazac.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Fentiazac.Approved, Investigational
LepirudinFentiazac may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanFentiazac may increase the anticoagulant activities of Letaxaban.Investigational
LevobetaxololFentiazac may decrease the antihypertensive activities of Levobetaxolol.Approved, Investigational
LevobunololFentiazac may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinFentiazac may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Fentiazac.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Fentiazac is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Fentiazac.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Fentiazac.Approved
LomefloxacinFentiazac may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Fentiazac is combined with Lornoxicam.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Fentiazac.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Fentiazac is combined with Loteprednol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Fentiazac.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Fentiazac.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Fentiazac is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Fentiazac.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Fentiazac is combined with Magnesium salicylate.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Fentiazac.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Fentiazac is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Fentiazac is combined with Meclofenamic acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Fentiazac is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Fentiazac is combined with Mefenamic acid.Approved
MelagatranFentiazac may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Fentiazac is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Fentiazac is combined with Meloxicam.Approved, Vet Approved
MepindololFentiazac may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineThe risk or severity of adverse effects can be increased when Fentiazac is combined with Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Fentiazac.Approved, Investigational, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Fentiazac.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Fentiazac.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Fentiazac is combined with Methylprednisolone.Approved, Vet Approved
MetipranololFentiazac may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Fentiazac.Approved
MetoprololFentiazac may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MicronomicinFentiazac may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Fentiazac.Approved, Experimental
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Fentiazac.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Fentiazac.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Fentiazac is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Fentiazac is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Fentiazac is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Fentiazac.Approved
MoxifloxacinFentiazac may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Fentiazac.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fentiazac.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Fentiazac is combined with Nabumetone.Approved
NadololFentiazac may decrease the antihypertensive activities of Nadolol.Approved
NadroparinFentiazac may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatFentiazac may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Fentiazac.Approved
Nalidixic AcidFentiazac may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Fentiazac is combined with Naproxen.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Fentiazac is combined with NCX 1022.Investigational
NeamineFentiazac may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololFentiazac may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NemonoxacinFentiazac may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinFentiazac may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Nepafenac.Approved, Investigational
NetilmicinFentiazac may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Fentiazac is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Fentiazac is combined with Niflumic Acid.Approved
NimesulideThe risk or severity of adverse effects can be increased when Fentiazac is combined with Nimesulide.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Fentiazac.Investigational
NorfloxacinFentiazac may increase the neuroexcitatory activities of Norfloxacin.Approved
OfloxacinFentiazac may increase the neuroexcitatory activities of Ofloxacin.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Fentiazac is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Fentiazac.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fentiazac.Approved
OlsalazineFentiazac may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Fentiazac is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatThe risk or severity of adverse effects can be increased when Fentiazac is combined with Omapatrilat.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Fentiazac.Vet Approved
OtamixabanFentiazac may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Fentiazac is combined with Oxaprozin.Approved
Oxolinic acidFentiazac may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololFentiazac may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Fentiazac.Approved, Withdrawn
PalmidrolThe risk or severity of adverse effects can be increased when Fentiazac is combined with Palmidrol.Experimental, Nutraceutical
PamidronateThe risk or severity of adverse effects can be increased when Fentiazac is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Fentiazac is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Fentiazac is combined with Parecoxib.Approved
ParomomycinFentiazac may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Fentiazac.Approved, Investigational
PazufloxacinFentiazac may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinFentiazac may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololFentiazac may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateFentiazac may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateFentiazac may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Fentiazac is combined with Perindopril.Approved
PhenindioneFentiazac may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonFentiazac may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Fentiazac is combined with Phenylbutazone.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fentiazac.Approved, Investigational
PindololFentiazac may decrease the antihypertensive activities of Pindolol.Approved, Investigational
Pipemidic acidFentiazac may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Fentiazac.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Fentiazac.Approved, Investigational
Piromidic acidFentiazac may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Fentiazac is combined with Piroxicam.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Fentiazac is combined with Pirprofen.Experimental
PitolisantThe risk or severity of adverse effects can be increased when Fentiazac is combined with Pitolisant.Approved, Investigational
Platelet Activating FactorFentiazac may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinFentiazac may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Fentiazac.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Fentiazac is combined with Pomalidomide.Approved
Potassium CitrateFentiazac may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
PractololFentiazac may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Fentiazac.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Fentiazac is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Fentiazac is combined with Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Fentiazac is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Fentiazac is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Fentiazac is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Fentiazac is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Fentiazac is combined with Pregnenolone.Approved, Experimental, Investigational
ProbenecidThe serum concentration of Fentiazac can be increased when it is combined with Probenecid.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Fentiazac is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Fentiazac.Approved, Investigational
PropafenoneFentiazac may decrease the antihypertensive activities of Propafenone.Approved
PropranololFentiazac may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Fentiazac is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Fentiazac is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Fentiazac.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Fentiazac.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Fentiazac.Vet Approved
Protein CFentiazac may increase the anticoagulant activities of Protein C.Approved
Protein S humanFentiazac may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeFentiazac may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinFentiazac may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Fentiazac.Investigational
PuromycinFentiazac may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Fentiazac is combined with Quinapril.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Fentiazac.Approved
RamiprilThe risk or severity of adverse effects can be increased when Fentiazac is combined with Ramipril.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Fentiazac is combined with Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Fentiazac is combined with Resveratrol.Approved, Experimental, Investigational
ReviparinFentiazac may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinFentiazac may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Fentiazac is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Fentiazac is combined with Risedronate.Approved, Investigational
RivaroxabanFentiazac may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Fentiazac is combined with Rofecoxib.Approved, Investigational, Withdrawn
RosoxacinFentiazac may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinFentiazac may increase the neuroexcitatory activities of Rufloxacin.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Fentiazac.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Fentiazac.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Fentiazac is combined with Salicylic acid.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Fentiazac is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Fentiazac.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Fentiazac.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Fentiazac.Approved, Investigational
SeliciclibThe risk or severity of adverse effects can be increased when Fentiazac is combined with Seliciclib.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Fentiazac.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Fentiazac.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Fentiazac.Investigational
SisomicinFentiazac may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinFentiazac may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium CitrateFentiazac may increase the anticoagulant activities of Sodium Citrate.Approved, Investigational
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Fentiazac.Approved
SotalolFentiazac may decrease the antihypertensive activities of Sotalol.Approved
SparfloxacinFentiazac may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpiraprilThe risk or severity of adverse effects can be increased when Fentiazac is combined with Spirapril.Approved
SpironolactoneFentiazac may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Fentiazac.Investigational
StreptomycinFentiazac may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Fentiazac is combined with Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Sulindac.Approved, Investigational
SulodexideFentiazac may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Fentiazac.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Fentiazac is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Fentiazac is combined with Suxibuzone.Experimental
TacrolimusFentiazac may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Fentiazac.Approved
TalinololFentiazac may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Fentiazac.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Fentiazac.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Fentiazac.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Fentiazac is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Fentiazac is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Fentiazac.Approved, Investigational
TemafloxacinFentiazac may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Fentiazac is combined with Temocapril.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Fentiazac is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Fentiazac is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Fentiazac is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Fentiazac.Vet Approved
TerbutalineFentiazac may decrease the antihypertensive activities of Terbutaline.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Fentiazac.Approved
TertatololFentiazac may decrease the antihypertensive activities of Tertatolol.Experimental
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Fentiazac is combined with Tiaprofenic acid.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Fentiazac is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololFentiazac may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Fentiazac.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Fentiazac is combined with Tixocortol.Approved, Withdrawn
TobramycinFentiazac may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Fentiazac.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Fentiazac is combined with Tolmetin.Approved
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Fentiazac.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Fentiazac is combined with Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Fentiazac.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Fentiazac.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Fentiazac.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Fentiazac is combined with Triamcinolone.Approved, Vet Approved
TriamtereneFentiazac may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Fentiazac is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Fentiazac.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Fentiazac.Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Fentiazac is combined with Trolamine salicylate.Approved
TrovafloxacinFentiazac may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinFentiazac may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Fentiazac is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Fentiazac.Approved, Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Fentiazac is combined with Valdecoxib.Approved, Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Fentiazac.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Fentiazac.Approved
WarfarinFentiazac may increase the anticoagulant activities of Warfarin.Approved
XimelagatranFentiazac may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Fentiazac.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Fentiazac.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Fentiazac is combined with Zofenopril.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Fentiazac is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Fentiazac.Withdrawn
Food Interactions
Not Available

References

General References
Not Available
External Links
KEGG Drug
D01975
ChemSpider
26854
BindingDB
50309254
ChEBI
94523
ChEMBL
CHEMBL589092
Wikipedia
Fentiazac
ATC Codes
M01AB10 — FentiazacM02AA14 — Fentiazac

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00136 mg/mLALOGPS
logP4.79ALOGPS
logP5.06ChemAxon
logS-5.4ALOGPS
pKa (Strongest Acidic)4.82ChemAxon
pKa (Strongest Basic)1.3ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area50.19 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity97.03 m3·mol-1ChemAxon
Polarizability34 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as 2,4,5-trisubstituted thiazoles. These are compounds containing a thiazole ring substituted at positions 2, 4 and 5 only.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Azoles
Sub Class
Thiazoles
Direct Parent
2,4,5-trisubstituted thiazoles
Alternative Parents
Chlorobenzenes / Aryl chlorides / Heteroaromatic compounds / Monocarboxylic acids and derivatives / Carboxylic acids / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Organochlorides / Organic oxides
show 2 more
Substituents
2,4,5-trisubstituted 1,3-thiazole / Chlorobenzene / Halobenzene / Aryl chloride / Aryl halide / Monocyclic benzene moiety / Benzenoid / Heteroaromatic compound / Carboxylic acid derivative / Azacycle
show 13 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Drug created on June 23, 2017 14:37 / Updated on June 02, 2018 08:47